ERBB2 and breast carcinoma: A subgroup analysis included 1095 patients with tumor size ranging from 1 to 10 mm, and Trastuzumab was shown to significantly reduce the risk of recurrence even in small HER2+ breast cancer patients (HR 0.61, 95%CI 0.38–0.99).